Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23495254 | 1.00 | MAPT (0.64) | MAPTTSHRALDH1A1KDM4EPOLB | |
| SCHEMBL23495266 | 0.90 | MAPT (0.64) | MAPTTSHRALDH1A1KDM4EPOLB | |
| SCHEMBL23495112 | 0.89 | MEN1 (0.68) | MAPTALDH1A1KDM4EPOLBTP53 | |
| SCHEMBL23495111 | 0.89 | MEN1 (0.68) | MAPTALDH1A1KDM4EPOLBTP53 | |
| SCHEMBL23495143 | 0.88 | KDM4E (0.63) | TSHRALDH1A1KDM4ETP53MEN1 | |
| SCHEMBL23495142 | 0.88 | KDM4E (0.63) | TSHRALDH1A1KDM4ETP53MEN1 | |
| SCHEMBL23495459 | 0.83 | MAPT (0.67) | MAPTTSHRALDH1A1KDM4EPOLB | |
| SCHEMBL23495250 | 0.79 | KDM4E (0.61) | MAPTALDH1A1KDM4EPOLBTP53 | |
| SCHEMBL29436166 | 0.79 | MEN1 (0.45) | MAPTTSHRALDH1A1KDM4EPOLB | |
| SCHEMBL29436158 | 0.79 | MEN1 (0.45) | MAPTTSHRALDH1A1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4248972-A2 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230293518-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-3877052-B1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11236065-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPECUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210179579-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179579-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | MAPT 1810/4885TSHR 3552/4885ALDH1A1 270/4885 |
| US-20230293518-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, MUSK, SMN1; SMN2 | MAPT 1863/4885TSHR 3553/4885ALDH1A1 308/4885 |
| US-11236065-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | MAPT 1810/4885TSHR 3552/4885ALDH1A1 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.